Cold agglutinin disease · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Fludarabine and Rituximab (FR) Variant #06 | — | R 117 749 | 28d | — | — | — | — | — |
Bendamustine and Rituximab (BR) Variant #12 | — | R 40 807 | 28d | ~42.3 mo | ~9.5 mo | ~46 | ~R 1 877 120 PFS proxy · indirect | 23 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 20 |
Eculizumab monotherapy N/A - secondary systemic drug | — | R 0 | — | — | — | — | — | — |
Sutimlimab monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
5 of 5 regimens shown